Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cutaneous lupus erythematosus Stories

2014-04-03 08:27:41

Lupus Science & Medicine is launched to provide the latest lupus research and stimulate collaborative efforts to improving the lives of all people affected by lupus WASHINGTON, April 3, 2014 /PRNewswire-USNewswire/ -- The Lupus Foundation of America and BMJ announced today the launch and publication of the first scientific research articles in Lupus Science & Medicine(TM). Lupus Science & Medicine is a peer reviewed, Open Access, online journal that provides a central point for...

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-03-18 23:02:43

Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com. According to the report, new product launches are set to fuel SLE and LN treatment markets expansion through to 2022. London, UK (PRWEB) March 18, 2014 The systemic Lupus Erythematosus (SLE) treatment market in the 7 major nations (the US, Germany, France, the UK, Italy, Japan,...

2014-03-17 12:27:32

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with its lead compound RSLV-132. Resolve administered the first doses to humans of RSLV-132 its first-in-class targeted nuclease therapy designed to decrease the burden of circulating RNA-containing immune complexes in SLE patients. Ongoing studies are designed to evaluate the safety, tolerability,...

2014-01-14 16:25:08

Brings Total to $6.6 Million to Educate Healthcare Professionals on Front-Lines of Care NEW YORK, Jan. 14, 2014 /PRNewswire/ -- The 2014 Omnibus Appropriations Bill released by the U.S. Congress last night provides $2 million to further the Lupus Initiative, the lupus provider education program conceived by the Lupus Research Institute (LRI) in collaboration with the federal government. Expected to pass this week, the appropriation will bring total support to $6.6 million for the...

2013-12-03 08:34:10

Benlysta Has Enabled SLE Patients to Decrease Their Steroid Dose Or Stop Taking Steroids Entirely, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 3, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 80 percent of surveyed rheumatologists agree that a steroid-sparing effect would be an important benefit of a new drug for the treatment of systemic lupus...

2013-11-26 12:25:29

Presents Mayor Michael R. Bloomberg with Distinguished Public Health Leadership Award NEW YORK, Nov. 26, 2013 /PRNewswire/ -- The S.L.E. Lupus Foundation and the Lupus Research Institute raised over $2 million at its annual Life Without Lupus Gala 2013 to support innovative novel research that can improve care while advancing towards a cure. Nearly 700 members of New York City's philanthropic, government, business, art, music and health care communities joined to help turn lupus...

2013-11-19 23:20:20

Reportbuyer.com just published a new market research report: EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022. London (PRWEB) November 19, 2013 EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022 Summary Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to...

Non-Toxic Therapy For Lupus Successfully Tested On Patients
2013-11-12 09:38:48

Rebekah Eliason for redOrbit.com – Your Universe Online Scientists from Northwestern Medicine have brought new hope to patients with lupus. A new nontoxic therapy that suppresses lupus in blood samples was designed and successfully tested on patients with the autoimmune disease. There is hope this treatment will replace the use of toxic drugs that carry nasty side effects with a vaccine like therapy. This new treatment could keep lupus in remission in the body. Lupus is a...

2013-11-04 08:27:21

ALBUQUERQUE, N.M., Nov. 4, 2013 /PRNewswire/ -- Exagen Diagnostics, Inc. and Capital Royalty Partners II, L.P. announced that they have closed a senior secured loan for up to $25 million of capital. Exagen is a patient-focused, discovery-driven, CLIA-registered, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focused on rheumatology. Exagen's lead test, SLE+, rules in-or-out Systemic Lupus Erythematosus (SLE) and provides results on 14 other...